Full Year 2023 Investor Presentation
11
Investor presentation
Full year 2023
Phase 3a trial with IcoSema successfully completed
IcoSema vs Insulin glargine U100 and insulin apart in subjects w/T2D
N=679
IcoSema ±OAD(s)
R
IGlar + IAsp + OAD(s)
1:1
52 weeks
5 weeks
follow-up
Change from baseline (%)
Headline trial results
Change in HbA1c
Change in body weight
Mean baseline HbA₁ 8.3%
Mean baseline body weight: 85.8 kg
3.2
Change from baseline (kg)
Primary endpoint:
Change in HbA1c from baseline
to week 53
•
Confirmatory secondary
endpoints:
Change in body weight from
baseline to week 52
.
Number of hypoglycaemic¹
episodes from baseline to week
57
-1.5%
-1.4%
-3.6*
IcoSema
IGlar + Iasp
IcoSema
IGlar + IAsp
0.26*
2.18
Injections per year
~52
~1450
Hypoglycaemic episodes¹
(rate per patient year)
Safety: IcoSema appeared to have safe and well-tolerated profile
*Statistically significant/superior vs. Insulin glargine U100 and insulin apart. 1 Level 2 and 3 hypoglycaemic episodes with blood glucose below 3.0 mmol/L
T2D: Type 2 diabetes; HbA1c: Glycated haemoglobin; BMI: Body Mass Index; OADs: Oral antidiabetic drugs.
Note: Trial objective: To confirm efficacy and compare safety of once weekly IcoSema compared with daily insulin glargine combined with insulin apart, both treatment arms with or without OADS in participants with T2D inadequately controlled with daily basal
insulin
Novo NordiskⓇView entire presentation